Advertisement
New Zealand markets closed
  • NZX 50

    11,717.43
    -117.59 (-0.99%)
     
  • NZD/USD

    0.6088
    +0.0004 (+0.07%)
     
  • NZD/EUR

    0.5680
    +0.0002 (+0.04%)
     
  • ALL ORDS

    8,013.80
    +11.00 (+0.14%)
     
  • ASX 200

    7,767.50
    +7.90 (+0.10%)
     
  • OIL

    81.46
    -0.28 (-0.34%)
     
  • GOLD

    2,336.90
    +0.30 (+0.01%)
     
  • NASDAQ

    19,682.87
    -106.16 (-0.54%)
     
  • FTSE

    8,164.12
    -15.56 (-0.19%)
     
  • Dow Jones

    39,118.86
    -45.20 (-0.12%)
     
  • DAX

    18,235.45
    +24.90 (+0.14%)
     
  • Hang Seng

    17,718.61
    +2.14 (+0.01%)
     
  • NIKKEI 225

    39,583.08
    +241.54 (+0.61%)
     
  • NZD/JPY

    97.9080
    +0.1750 (+0.18%)
     

One Sight Sciences Insider Raised Stake By 34% In Previous Year

Insiders were net buyers of Sight Sciences, Inc.'s (NASDAQ:SGHT ) stock during the past year. That is, insiders bought more stock than they sold.

While insider transactions are not the most important thing when it comes to long-term investing, we would consider it foolish to ignore insider transactions altogether.

View our latest analysis for Sight Sciences

The Last 12 Months Of Insider Transactions At Sight Sciences

In the last twelve months, the biggest single purchase by an insider was when Independent Chairman Staffan Encrantz bought US$1.8m worth of shares at a price of US$3.46 per share. Even though the purchase was made at a significantly lower price than the recent price (US$6.83), we still think insider buying is a positive. Because the shares were purchased at a lower price, this particular buy doesn't tell us much about how insiders feel about the current share price.

ADVERTISEMENT

Staffan Encrantz bought 985.12k shares over the last 12 months at an average price of US$3.04. You can see a visual depiction of insider transactions (by companies and individuals) over the last 12 months, below. If you want to know exactly who sold, for how much, and when, simply click on the graph below!

insider-trading-volume
insider-trading-volume

Sight Sciences is not the only stock that insiders are buying. For those who like to find small cap companies at attractive valuations, this free list of growing companies with recent insider purchasing, could be just the ticket.

Sight Sciences Insiders Are Selling The Stock

Over the last three months, we've seen significant insider selling at Sight Sciences. In total, insiders sold US$244k worth of shares in that time, and we didn't record any purchases whatsoever. Overall this makes us a bit cautious, but it's not the be all and end all.

Insider Ownership

Many investors like to check how much of a company is owned by insiders. A high insider ownership often makes company leadership more mindful of shareholder interests. Insiders own 20% of Sight Sciences shares, worth about US$68m. This level of insider ownership is good but just short of being particularly stand-out. It certainly does suggest a reasonable degree of alignment.

So What Does This Data Suggest About Sight Sciences Insiders?

Insiders sold stock recently, but they haven't been buying. In contrast, they appear keener if you look at the last twelve months. It's good to see insiders are shareholders. So we're happy enough to look past some selling. In addition to knowing about insider transactions going on, it's beneficial to identify the risks facing Sight Sciences. For example - Sight Sciences has 3 warning signs we think you should be aware of.

Of course Sight Sciences may not be the best stock to buy. So you may wish to see this free collection of high quality companies.

For the purposes of this article, insiders are those individuals who report their transactions to the relevant regulatory body. We currently account for open market transactions and private dispositions of direct interests only, but not derivative transactions or indirect interests.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com